Valuation Pelthos Therapeutics Inc.

Stocks

Market Closed - NYSE 00:00:00 05/09/2026 +04			5-day change	1st Jan Change
24.35 ^USD	-0.04%		-1.54%	-21.45%

08-14	Oppenheimer Adjusts Pelthos Therapeutics PT to $64 From $66, Maintains Outperform Rating	MT
08-13	Pelthos Therapeutics Inc., Q2 2026 Earnings Call, Aug 13, 2026

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027	2028
Market Cap ¹	3.864	95.69	93.22	-	-
Change	-	2,376.4%	-2.57%	-	-
Enterprise Value (EV)	3.864	95.69	93.22	93.22	93.22
Change	-	2,376.4%	-2.57%	0%	0%
P/E	-0.45x	-1.35x	-1.42x	-8.66x	10.6x
PBR	-	-	-	-	-
PEG	0x	-0x	0.1x	0.1x	-0x
Capitalization / Revenue	-	5.7x	1.46x	0.83x	0.59x
EV / Revenue	-	0x	1.46x	0.83x	0.59x
EV / EBITDA	-	-0x	-2.94x	13.9x	3.95x
EV / EBIT	-	-0x	-1.94x	-10.7x	4.15x
EV / FCF	-	-	-8.47x	93.2x	2.07x
FCF Yield	-	-	-11.8%	1.07%	48.3%
Dividend per Share ²	-	-	-	-	-
Rate of return	-	-	-	-	-
EPS ²	-14.3	-23.04	-17.12	-2.813	2.302
Distribution rate	-	-	-	-	-
Net sales ¹	-	16.8	63.75	112.2	159.2
EBITDA ¹	-	-24.68	-31.75	6.7	23.6
EBIT ¹	-	-32.43	-47.97	-8.737	22.46
Net income ¹	-7.955	-43.32	-62.08	-24.96	10.79
Net Debt	-	-	-	-	-
Reference price ²	6.41	31.00	24.35	24.35	24.35
Nbr of stocks (in thousands)	603	3,087	3,828	-	-
Announcement Date	27/03/25	19/03/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
PELTHOS THERAPEUTICS INC.	-1.42x	-	-	-	93.22M
ELI LILLY AND COMPANY	32.72x	11.9x	24.26x	0.6%	1,024B
JOHNSON & JOHNSON	30.62x	-	-	1.95%	663B
ABBVIE INC.	32.73x	7.6x	15.8x	2.67%	453B
ROCHE HOLDING AG	19.89x	4.73x	11.71x	2.8%	352B
NOVARTIS AG	22.72x	5.84x	14.51x	2.7%	304B
ASTRAZENECA PLC	20.87x	4.29x	12.24x	2.06%	252B
AMGEN INC.	27.66x	7.14x	13.15x	2.31%	236B
NOVO NORDISK A/S	13.33x	4.82x	10.06x	3.78%	206B
GILEAD SCIENCES, INC.	-46.14x	6.65x	25.95x	2.18%	187B
Average	15.30x	6.62x	15.96x	2.34%	367.85B
Weighted average by Cap.	24.05x	7.99x	17.80x	1.95%